Recently, Kern et al. 1 reported a new biological subentity within patients with acute myeloid leukemia (AML). The authors identified 20 out of 1094 patients presenting with limited differentiation (AML-LD) and a distinct immunophenotype (cyMPO pos CD33 pos CD56 pos/neg and negativity for CD13, CD34 and HLA-DR). Further characterization indicated that the leukemic clone in these patients did not express other myelomonocytic antigens and, on the molecular level, all patients were positive for the NPM1 type A mutation. Based on these findings, the authors suggested the presence of a homogeneous genetic background within this AML subgroup. The molecular definition is important to better characterize the heterogeneous group of patients with AML and to identify potential targets for accurate diagnosis, assessment of prognosis and improved treatment strategies. In this aspect, we were interested in this novel population and aimed to verify its existence in a cohort of AML patients investigated prospectively within the study alliance leukemia (SAL).
We performed routine leukemia diagnostics, including immunophenotyping, molecular and cytogenetic analyses, and cytomorphology in 1435 patients with AML enrolled in different multicenter studies of the SAL study group. Based on the immunophenotype described by Kern et al., 1 we identified a group of 29 patients (2.0%). In addition to the special immunophenotypic criteria and in line with the data reported by Kern et al., 1 all of these patients had a normal karyotype, showed an increased median leukocytes count of 44 GPT/l (range: 2-267 GPT/l) and presented predominantly with cytomorphological characteristics of AML M1 (Table 1) . Furthermore, we looked for the presence of the cup-like morphology, 2 a distinct morphological subgroup having a nuclear invagination, and found that 75% of the analyzed patients showed this morphology, which is slightly higher than in the population described by the Munich group. In addition, the median age of our cohort was significantly lower than that described by Kern et al. 1 (53 versus 70 years, Po0.0001). The reported prevalence of NPM1 mutations in unselected patients with AML ranges from 25 to 35%. 3 In line with this, the overall prevalence of NPM1 mutations in the investigated AML patients enrolled in the above mentioned SAL studies was 30.8% (442/1435). The previous study by Kern et al.
1 found NPM1 mutations in all patients with AML-LD, However, when we correlated the flow cytometric data with the molecular analyses in our patients, only 27 of our 29 individuals showed NPM1 mutations in exon 12. To investigate the presence of mutations outside this region, we sequenced the NPM1-mRNA corresponding to exons 9-11. In one patient, we could indeed identify a 19 bp deletion mutation in exon 10, leading to a deduced frameshift starting at AA 252 and inducing a premature stop of translation at codon 265. In the second patient, no such mutation in NPM1 could be identified. However, a comparison of the immunophenotype of this patient including antigens like CD2, CD7 and CD19 indicated that this patient was the only one who expressed CD7 aberrantly, a marker that is rarely seen in AML with mutant NPM1 as recently reported 4 and confirmed in our updated data set of 538 AML patients (CD7 pos 13.1% wtNPM1 versus 5.0% mNPM1, P ¼ 0.0027; unpublished data). Thus, the inclusion of CD7, CD2 and CD19 negativity as criterion might further strengthen the special phenotypic subentity reported by Kern et al. Furthermore, within the patients with exon 12 NPM1 mutations, only 24/27 had a type A mutation, one additional patient had a type D mutation and two patients showed other NPM1 mutations (DD-3/CAGA and DD-43/CAAG). Based on these results, it appears more likely that not the type of NPM1 mutation but the presence of the mutation is associated with the development of this particular immunophenotype.
Taken together, our data clearly support Kern and et al. in their description of a novel subgroup of patients presenting with a distinct immunophentotypic, molecular and morphologic profile. However, our data also suggest that the NPM1 mutations present in this group are not restricted to the most common type A, but may include other exon 12 variants as well as rare mutations outside exon 12. In addition, the analysis of lymphocytic antigens like CD2, CD7 and CD19 might help to more precisely describe the relevant subpopulation.
In conclusion, our data support the presence of the distinct immunophenotypic subgroup first described by Kern et al.
1 with a prevalence of 2% in unselected AML patients. It will be interesting to see whether this subgroup could be further characterized by a particular clinical behavior. Preliminary data in our own cohort indicated that only 33% (7 of 21 evaluable patients) achieved a complete remission after conventional double induction, a rate that is significantly lower than observed in the entire population of patients with normal karyotype AML in the respective SAL studies (68.4%, 450/658 patients, P ¼ 0.002, Fisher's exact test). Although obtained from different protocols and based on small numbers, if these data could be confirmed independently, it would make the detection of this subgroup also relevant from a clinical point of view. Table 1 Laboratory and clinical characteristics of the described AML patients Abbreviations: AML, acute myeloid leukemia; CR, complete remission after double induction therapy; cyMPO, cytoplasmic myeloperoxidase by flow cytometry; F, female; FLT3-ITD, FLT3 internal tandem duplication; M, male; ND, not determined; NK, normal karyotype; POX, peroxidase by cytochemistry.
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